Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.46 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.46 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20344316 | 0.87 | SMN1; SMN2 (0.54) | SMN1; SMN2ALDH1A1KDM4ECARM1PRMT6 | |
| SCHEMBL24019182 | 0.80 | SMN1; SMN2 (0.48) | SMN1; SMN2ALDH1A1KDM4ECARM1PRMT6 | |
| SCHEMBL24019177 | 0.80 | MAPT (0.48) | SMN1; SMN2ALDH1A1KDM4EMAPTLMNA | |
| SCHEMBL20340696 | 0.79 | KDM4E (0.53) | SMN1; SMN2ALDH1A1KDM4ECARM1PRMT6 | |
| Dibemethine SCHEMBL276863 | 0.78 | ALDH1A1 (0.70) | SMN1; SMN2ALDH1A1KDM4ECARM1PRMT6 | |
| Dibemethine SCHEMBL10542007 | 0.78 | ALDH1A1 (0.70) | SMN1; SMN2ALDH1A1KDM4ECARM1PRMT6 | |
| SCHEMBL28335587 | 0.78 | SMN1; SMN2 (0.63) | SMN1; SMN2ALDH1A1KDM4ECARM1PRMT6 | |
| SCHEMBL20338984 | 0.78 | SMN1; SMN2 (0.52) | SMN1; SMN2ALDH1A1KDM4ECARM1PRMT6 | |
| SCHEMBL26601836 | 0.78 | SMN1; SMN2 (0.46) | SMN1; SMN2ALDH1A1KDM4ECARM1PRMT6 | |
| SCHEMBL20339016 | 0.77 | MAPT (0.54) | SMN1; SMN2KDM4ETSHRGAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11739072-B2 | Heteroaryl compounds and their use | MINORYX THERAPEUTICS S.L. (ES) | 2023-08-29 | — | — | US | disclosed |
| US-11739072-B2 | Heteroaryl compounds and their use | MINORYX THERAPEUTICS S.L. (ES) | 2023-08-29 | — | — | US | disclosed |
| US-11739072-B2 | Heteroaryl compounds and their use | MINORYX THERAPEUTICS S.L. (ES) | 2023-08-29 | — | — | US | disclosed |
| US-20220135535-A1 | HETEROARYL COMPOUNDS AND THEIR USE | MINORYX THERAPEUTICS S.L. (ES) | 2022-05-05 | — | — | US | disclosed |
| US-20220135535-A1 | HETEROARYL COMPOUNDS AND THEIR USE | MINORYX THERAPEUTICS S.L. (ES) | 2022-05-05 | — | — | US | disclosed |
| EP-3562811-B1 | HETEROARYL COMPOUNDS AND THEIR USE | MINORYX THERAPEUTICS S L (ES) | 2022-03-16 | — | — | EP | disclosed |
| US-11174242-B2 | Heteroaryl compounds and their use | MINORYX THERAPEUTICS S.L. (ES) | 2021-11-16 | — | — | US | disclosed |
| US-11174242-B2 | Heteroaryl compounds and their use | MINORYX THERAPEUTICS S.L. (ES) | 2021-11-16 | — | — | US | disclosed |
| US-20190337922-A1 | HETEROARYL COMPOUNDS AND THEIR USE | MINORYX THERAPEUTICS S.L. (ES) | 2019-11-07 | — | — | US | disclosed |
| EP-3562811-A1 | HETEROARYL COMPOUNDS AND THEIR USE | Minoryx Therapeutics S.L. (ES) | 2019-11-06 | — | — | EP | disclosed |
| WO-2018122775-A1 | HETEROARYL COMPOUNDS AND THEIR USE | MINORYX THERAPEUTICS S.L. (ES) | 2018-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220135535-A1 | HETEROARYL COMPOUNDS AND THEIR USE | GBA1, GBA2, GAA | SMN1; SMN2 36/4885ALDH1A1 1097/4885KDM4E 4446/4885 |
| US-20190337922-A1 | HETEROARYL COMPOUNDS AND THEIR USE | GBA1, GBA2, GAA | SMN1; SMN2 36/4885ALDH1A1 1097/4885KDM4E 4446/4885 |
| US-11174242-B2 | Heteroaryl compounds and their use | GBA1, GBA2, GAA | SMN1; SMN2 36/4885ALDH1A1 1097/4885KDM4E 4446/4885 |
| US-11739072-B2 | Heteroaryl compounds and their use | GBA1, GBA2, GAA | SMN1; SMN2 36/4885ALDH1A1 1097/4885KDM4E 4446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.